MA29888B1 - Antagonistes du recepteur d'histamine h3 - Google Patents

Antagonistes du recepteur d'histamine h3

Info

Publication number
MA29888B1
MA29888B1 MA30879A MA30879A MA29888B1 MA 29888 B1 MA29888 B1 MA 29888B1 MA 30879 A MA30879 A MA 30879A MA 30879 A MA30879 A MA 30879A MA 29888 B1 MA29888 B1 MA 29888B1
Authority
MA
Morocco
Prior art keywords
compound
formula
disorders
disorder
disease
Prior art date
Application number
MA30879A
Other languages
English (en)
Inventor
Travis T Wager
Ramalakshmi Yegna Chandrasekaran
Todd William Butler
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA29888B1 publication Critical patent/MA29888B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

CETTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE I TELLE QUE DÉFINIE ICI OU UN SEL ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE DE CELUI-CI ; UNE COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSÉ DE FORMULE I, UN PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ DE FORMULE I, UN PROCÉDÉ DE TRAITEMENT D'UN TROUBLE OU D'UNE AFFECTION QUI PEUT ÊTRE TRAITÉ EN INHIBANT LES RÉCEPTEURS DE L'HISTAMINE H3, LEDIT PROCÉDÉ COMPRENANT D'ADMINISTRER À UN MAMMIFÈRE QUI A BESOIN D'UN TEL TRAITEMENT UN COMPOSÉ DE FORMULE I TEL QUE DÉCRIT CI-DESSUS, ET UN PROCÉDÉ DE TRAITEMENT D'UN TROUBLE OU D'UNE AFFECTION SÉLECTIONNÉ DANS LE GROUPE CONSTITUÉ DE LA DÉPRESSION, DE TROUBLES DE L'HUMEUR, DE LA SCHIZOPHRÉNIE, DE TROUBLES DE L'ANXIÉTÉ, DE LA MALADIE D'ALZHEIMER, DU TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH), DE TROUBLES PSYCHOTIQUES, DE TROUBLES COGNITIFS, DE TROUBLES DU SOMMEIL, DE L'OBÉSITÉ, DE VERTIGES, DE L'ÉPILEPSIE, DU MAL DES TRANSPORTS, DE MALADIES RESPIRATOIRES, DE L'ALLERGIE, DE RÉPONSES DES VOIES RESPIRATOIRES INDUITES PAR UNE ALLERGIE, DE LA RHINITE ALLERGIQUE, DE L'OBSTRUCTION NASALE, DE LA CONGESTION ALLERGIQUE, DE LA CONGESTION, DE L'HYPOTENSION, DE MALADIES CARDIOVASCULAIRES, DE MALADIES DU TRACTUS GASTRO-INTESTINAL, DE L'HYPERMOTILITÉ ET DE L'HYPOMOTILITÉ ET DE LA SÉCRÉTION ACIDE DU TRACTUS GASTRO-INTESTINAL, LEDIT PROCÉDÉ COMPRENANT D'ADMINISTRER À UN MAMMIFÈRE QUI A BESOIN D'UN TEL TRAITEMENT UN COMPOSÉ DE FORMULE I TEL QUE DÉCRIT CI-DESSUS.
MA30879A 2005-10-27 2008-04-25 Antagonistes du recepteur d'histamine h3 MA29888B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73099605P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
MA29888B1 true MA29888B1 (fr) 2008-10-03

Family

ID=37776539

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30879A MA29888B1 (fr) 2005-10-27 2008-04-25 Antagonistes du recepteur d'histamine h3

Country Status (39)

Country Link
US (2) US8158673B2 (fr)
EP (1) EP1951660B1 (fr)
JP (2) JP4319245B2 (fr)
KR (1) KR101025358B1 (fr)
CN (1) CN101296898B (fr)
AP (1) AP2403A (fr)
AR (1) AR056879A1 (fr)
AU (1) AU2006307645B2 (fr)
BR (1) BRPI0617797A2 (fr)
CA (1) CA2621323C (fr)
CR (1) CR9910A (fr)
CU (1) CU23806B7 (fr)
DK (1) DK1951660T3 (fr)
DO (1) DOP2006000239A (fr)
EA (1) EA013602B1 (fr)
EC (1) ECSP088373A (fr)
ES (1) ES2444370T3 (fr)
GE (1) GEP20104937B (fr)
GT (1) GT200600471A (fr)
HN (1) HN2006036385A (fr)
HR (1) HRP20140061T1 (fr)
IL (1) IL189866A (fr)
MA (1) MA29888B1 (fr)
MY (1) MY145001A (fr)
NI (1) NI200800132A (fr)
NL (1) NL1032713C2 (fr)
NO (1) NO20082264L (fr)
NZ (1) NZ566488A (fr)
PE (1) PE20070720A1 (fr)
PL (1) PL1951660T3 (fr)
PT (1) PT1951660E (fr)
RS (2) RS20080173A (fr)
SI (1) SI1951660T1 (fr)
TN (1) TNSN08150A1 (fr)
TW (1) TWI318206B (fr)
UA (1) UA88719C2 (fr)
UY (1) UY29882A1 (fr)
WO (1) WO2007049123A1 (fr)
ZA (1) ZA200803130B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP4585610B2 (ja) * 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
EP2123644B1 (fr) 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Dérivés de benzodiazépine et utilisation de ces derniers
DK2195293T3 (da) 2007-08-22 2014-02-03 Astrazeneca Ab Cyclopropylamidderivater
CN101939306A (zh) * 2007-12-07 2011-01-05 美国辉瑞有限公司 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
CA2721303C (fr) * 2008-05-08 2016-06-28 Evotec Ag Azetidines et cyclobutanes comme antagonistes des recepteurs h3 de l'histamine
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
BR112012020629A2 (pt) 2010-02-18 2018-06-19 Astrazeneca Ab forma cristalina, e, método para a terapia de um distúrbio
CA2830027C (fr) 2011-03-31 2016-04-26 Pfizer Inc. Nouvelles pyridones bicycliques
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
EP2867236B1 (fr) 2012-06-29 2017-06-14 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
EP3083618B1 (fr) 2013-12-17 2018-02-21 Pfizer Inc Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016012896A1 (fr) 2014-07-24 2016-01-28 Pfizer Inc. Composés de pyrazolopyrimidine
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
PT3478679T (pt) 2016-07-01 2021-06-30 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas
AU2018230236B2 (en) 2017-03-10 2022-05-19 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
EP3634978A1 (fr) 2017-06-07 2020-04-15 Adrx, Inc. Inhibiteur d'agrégation de tau
IL271290B2 (en) 2017-06-22 2023-11-01 Pfizer Dihydro-pyrrolo-pyridine derivatives
EP3668886A2 (fr) 2017-08-18 2020-06-24 Adrx, Inc. Inhibiteurs peptidiques d'agrégation de tau
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
CN116514645A (zh) * 2023-04-08 2023-08-01 绍兴上虞华伦化工有限公司 二氟-4溴苯甲醛及其制备工艺
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
JP2004131497A (ja) * 2002-09-18 2004-04-30 Satoshi Shuto シスシクロプロパン誘導体
WO2005009976A1 (fr) * 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl-piperazines et leur utilisation en tant que ligands du recepteur histaminique h3
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP1720847A1 (fr) 2004-02-02 2006-11-15 Pfizer Products Incorporated Modulateurs du recepteur de l'histamine-3
BRPI0509298A (pt) * 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (fr) 2004-05-12 2005-11-16 Pfizer Limited Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP4585610B2 (ja) * 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物

Also Published As

Publication number Publication date
WO2007049123A1 (fr) 2007-05-03
KR101025358B1 (ko) 2011-03-28
US20080096955A1 (en) 2008-04-24
JP2009161554A (ja) 2009-07-23
DK1951660T3 (da) 2014-01-27
IL189866A (en) 2012-06-28
CA2621323C (fr) 2010-08-24
NO20082264L (no) 2008-07-22
JP5064427B2 (ja) 2012-10-31
NL1032713A1 (nl) 2007-05-01
PT1951660E (pt) 2014-02-10
GT200600471A (es) 2007-06-08
NI200800132A (es) 2010-02-15
TNSN08150A1 (fr) 2009-10-30
JP2009513619A (ja) 2009-04-02
RS53153B (sr) 2014-06-30
CN101296898B (zh) 2013-07-24
MY145001A (en) 2011-12-15
AU2006307645B2 (en) 2012-02-16
US20120220568A1 (en) 2012-08-30
AR056879A1 (es) 2007-10-31
KR20080054413A (ko) 2008-06-17
CU23806B7 (es) 2012-04-15
PL1951660T3 (pl) 2014-04-30
GEP20104937B (en) 2010-03-25
CN101296898A (zh) 2008-10-29
EP1951660B1 (fr) 2013-12-11
AP2008004401A0 (en) 2008-04-30
SI1951660T1 (sl) 2014-02-28
HK1124831A1 (en) 2009-07-24
EP1951660A1 (fr) 2008-08-06
AU2006307645A1 (en) 2007-05-03
ZA200803130B (en) 2009-01-28
IL189866A0 (en) 2008-11-03
AP2403A (en) 2012-05-04
CR9910A (es) 2008-05-16
RS20080173A (sr) 2009-07-15
ECSP088373A (es) 2008-05-30
UA88719C2 (ru) 2009-11-10
ES2444370T3 (es) 2014-02-24
BRPI0617797A2 (pt) 2011-08-09
JP4319245B2 (ja) 2009-08-26
CA2621323A1 (fr) 2007-05-03
CU20080069A7 (es) 2009-12-17
US8158673B2 (en) 2012-04-17
EA013602B1 (ru) 2010-06-30
HRP20140061T1 (hr) 2014-02-14
DOP2006000239A (es) 2007-04-30
UY29882A1 (es) 2007-05-31
HN2006036385A (es) 2009-10-30
TWI318206B (en) 2009-12-11
PE20070720A1 (es) 2007-08-11
US8389743B2 (en) 2013-03-05
NL1032713C2 (nl) 2007-10-09
EA200800946A1 (ru) 2008-10-30
NZ566488A (en) 2011-07-29
TW200800886A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
MA29888B1 (fr) Antagonistes du recepteur d'histamine h3
ATE488496T1 (de) Histamin-3-rezeptorantagonisten
WO2007105053A3 (fr) Tétralines en tant qu'antagonistes du récepteur h-3
WO2007088450A3 (fr) Chromane antagoniste du récepteur h-3
WO2007063385A3 (fr) Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
WO2007138431A3 (fr) Antagonistes de l'éther histamine-3 azabicyclique
MA27847A1 (fr) Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.
EA018064B1 (ru) Способ лечения депрессии
BRPI0513486A (pt) derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3
MA35194B1 (fr) Derives de benzamide substitues
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
US11173147B2 (en) Prophylactic or therapeutic agent for delirium
HRP940960A2 (en) N-substituted azabicycloheptane derivatives, the preparation and use thereof
US11547707B2 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP3171261B2 (ja) 神経弛緩薬等としてのｎ−置換された３−アザビシクロ［３．２．０］ヘプタン誘導体
JP2022031814A (ja) 不安障害を治療するための（２Ｓ）－１－［４－（３，４－ジクロロフェニル）ピペリジン－１－イル］－３－［２－（５－メチル－１，３，４－オキサジアゾール－２－イル）ベンゾ［ｂ］フラン－４－イルオキシ］プロパン－２－オールまたはその代謝産物
MX2007003587A (es) Antagonistas de los receptores de histamina-3.
BRPI0514820A (pt) antagonistas de receptor de histamina-3 amina azabicìclicos
BRPI0512567A (pt) compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
AR037711A1 (es) Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP4888751B2 (ja) トリフルオロプロピルアミノペンタン誘導体及びその製造方法
OA20885A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder.
TH88617A (th) ฮิสทามีน-3 รีเซพเตอร์ แอนทาโกนิสท์
TH78676A (th) ไดเฟนิลอีเธอร์ลิแกนด์ที่ใช้รักษาโรค